Toyama Licenses Cempra's Solithromycin Antibiotic For Japan Market
This article was originally published in PharmAsia News
Executive Summary
Toyama Chemical has licensed Cempra's solithromycin antibiotic for treating pneumonia and expects to begin clinical trials in Japan with a goal of applying for marketing approval within the next five years.